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Anticoagulant treatment does not affect the action of flavone acetic acid
in tumour-bearing mice
G. Thurston, K.A. Smith & J.C. Murray
CRC Gray Laboratory, Mount Vernon Hospital, PO Box 100, Northwood, Middlesex HA6 2JR, UK.
Summary Flavone acetic acid (FAA) is a novel antitumour agent that has a profound effect on the
vasculature in murine tumour models. Previously we have shown that FAA induces a coagulopathy and
thrombocytopaenia in tumour-bearing mice, and the purpose of the present study was to determine the
significance of the FAA-induced intravascular coagulation in the antitumour action of FAA. Several
anticoagulant agents were tested for their effectiveness in altering ex vivo coagulation of murine plasma;
heparin and ancrod were found to be most effective. These agents were administered to tumour-bearing mice
prior to FAA and TNF treatment with little effect on the induced regrowth delay. However: the FAA-induced
consumption of platelets in tumour-bearing mice was not blocked by anticoagulant treatment. These data
suggest that platelet consumption occurs independently of the normal coagulation pathway, and further that
fibrin deposition may not be a major factor in the antitumour action of FAA.
While FAA has been shown to be an effective agent against
many murine solid tumours, it has been ineffective in the
clinic. In view of the similarities in their anti-tumour effects
in mice (i.e. greater effect in vivo than in vitro, steep dose
response curves, and greater toxicity towards solid tumours
in which they cause a decrease in blood flow and rapid
haemorrhagic necrosis,) FAA has been compared to the
natural cytokine tumour necrosis factor (TNF) (Finlay et al.,
1988). However, the mechanism of antitumour action of both
FAA and TNF is still controversial and the reasons for
failure in the clinic remain unclear.
TNF is a potent mediator of many cellular responses in
vitro. Important among these are local effects on coagulation,
such as the induction of tissue factor (thromboplastin) on the
surface of endothelial cells (Nawroth & Stern, 1986; Bevilac-
qua et al., 1986). In vivo, TNF has also been shown to induce
fibrin deposition specifically within fibrosarcomas (Nawroth
et al., 1988). In a similar manner, FAA is able to induce
procoagulant activity in endothelial cells in vitro (Murray et
al., 1991a), while in vivo, FAA significantly alters the coag-
ulation properties of plasma in tumour-bearing mice and
causes a dose dependent thrombocytopaenia at early times
after treatment (Murray et al., 1989). It has been postulated
that local changes in coagulation may be the mechanism by
which TNF, and possibly FAA, induce reduction of tumour
blood flow, eventually leading to haemorrhagic necrosis
(Nawroth et al., 1988; Shimomura et al., 1988; Murray et al.,
1989).
To test the hypothesis that change in coagulation proper-
ties are relevant to the action of FAA, we tested several
different anticoagulant agents for their effect on the coagula-
tion properties of murine plasma using the clotting time (CT)
and the prothrombin time (PT) assays; we found that heparin
and ancrod were effective anticoagulants in vivo. These were
tested for their effect on the antitumour action of both FAA
and TNF, using regrowth delay assay with the CaNT car-
cinoma. In addition, platelet numbers and coagulation para-
meters which had been shown to change markedly in
tumour-bearing mice following FAA treatment were mea-
sured.
Materials and methods
Mice and tumours
Experiments were performed with 12-16 week old male
CBA/HtBSVS mice. The tumour used in the study was the
CaNT tumour, a moderately differentiated adenocarcinoma
passaged in syngeneic mice. Tumours were implanted sub-
cutaneously on the back as described elsewhere (Smith et al.,
1988).
Drugs and administration
FAA was generously provided by Lipha Pharmaceutical
(Lyon, France) and was used as described previously (Mur-
ray et al., 1989). TNFa (108 U mg-') was obtained from
Hoffman La Roche and injected intravenously at a dose of
20 jsg/mouse. A range of anticoagulants was tested. These are
listed in Table I and their main sites of activity indicated. All
anticoagulants were obtained from Sigma Chemicals. Hepa-
rin was made up in sterile saline and injected into one of the
laterial tail veins in a constant volume (0.01 mg g'). War-
farin was made up in distilled water and given to mice in
drinking water over a 4 to 7 day period. Ancrod, hirudin,
streptokinase and urokinase were all made up in sterile saline
and injected via a lateral tail vein in a constant volume of
0.2 ml per mouse. In all urokinase tests, heparin (100 U kg-')
was given 15 min prior to urokinase injection. Each drug was
tested at a range of doses (Table I), based initially on
previously published results, or by extrapolation from clinical
dosages.
Plasma collection and coagulant assays
The collection of mouse plasma and the ex vivo coagulation
assays and platelet counts have been described previously
(Murray et al., 1989). Anaesthetised mice were injected in-
Table I Anticoagulant tested in CBA mice
Name Effect Doses tested
Heparin Inhibits thrombin 500 U kg-' i.v.
200
100
Ancrod Depletes fibrinogen 5 U kg-' i.v.
2
1
Hirudin Inhibits thrombin 50 U/mouse i.v.
5
Streptokinase Dissolves fibrin clots 400 U/mouse i.v.
100
Urokinase + Heparin Dissolves fibrin clots 0.5 U/mouse i.v.
(100 Ugr') 0.1
0.01
Warfarin Inhibits synthesis of 1.0 mg 1-I oral
vitamin K enzymes 0.25
List of anticoagulant agents tested in this study, their major site of
antithrombotic action, and the doses tested.
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travenously via one of the lateral tail veins with 0.4 ml of
0.1 M sodium citrate. The anti-coagulated blood was then
immediately taken by opening the chest cavity, severing the
aorta, and extracting the blood from the chest cavity. Platelet
counts were obtained using a Coulter Counter in the Depart-
ment of Haematology, Mount Vernon Hospital. Citrated
plasma samples were frozen at - 20°C until tested. The ex
vivo clotting assays were performed on thawed citrated plas-
ma samples essentially as described in Dacie & Lewis (1984).
Briefly, a 0.1 ml volume of test plasma was thawed to 4°C
and kept on ice. For the prothrombin (PT) assay, 0.1 ml of
rabbit brain thromboplastin (Manchester Comparative Rea-
gents, UK) was added to the sample, followed by 0.1 ml of
0.025 M CaCl2 solution, the solution was mixed and heated in
a water bath at 37°C. The time until formation of visible
fibrin strands was measured. For the clotting time (CT)
assay, 0.1 ml of test plasma was combined with 0.1 ml of
PBS and 0.1 ml of CaCl2, heated to 37°C and the time until
formation of visible fibrin strands was measured.
Regrowth delay assay
Mice were treated with drugs when tumours have reached 6
to 8 mm mean diameter. For experiments with heparin, mice
were given the drug 15 min prior to FAA or TNF, followed
by repeated injections of heparin 90 and 180 min after the
initial injection. Mice given heparin alone had the same
schedule. For experiments with ancrod, mice were given a
single dose of ancrod 30 min prior to FAA or TNF adminis-
tration. Tumours were measured at intervals of 2 or 3 days
and the mean diameter calculated.
Results
Ex vivo coagulation assays
In order to establish the effective dosage of the various
anticoagulants in mice, the drugs were administered to non-
tumour bearing CBA mice and the plasma extracted and
tested for coagulation parameters. Table I shows a summary
of the drugs and doses used in the study, and their mode of
action. Heparin and ancrod were found to be most effective
at preventing clotting in ex vivo assays, while streptokinase,
warfarin, hirudin and urokinase + heparin all had no effect
on ex vivo clotting times. At the highest doses testes, heparin
produced extensive bleeding at the i.v. injection site, while
after ancrod the mice appeared ill for perhaps 4 h before
recovering. In general, the mice tolerated the high doses well.
Mice treated with heparin at a dose of 500 U kg showed a
significant increase in both clotting time (CT), and prothrom-
bin time (PT); Table I shows the time course of CT and PT
for non-tumour bearing mice following intravenous injection
of heparin or ancrod. The control values (no treatment) are
shown at time 0. For the CT assay, formation of fibrin
strands, which marks the completion of the assay, was not
observed in murine plasma until at least 120 min after
heparin administration. By 360 min, the CT had returned to
near control levels. For the PT assay, clot formation was not
observed for at least 60 min following heparin injection, and
by 360 min clot formation had returned to control values.
Ancrod was also an effective anticoagulant agent in mice.
Table II shows CT and PT as a function of time after ancrod
administration (5 U kg-'). The effect was more prolonged
than that of heparin and the plasma was unable to clot in the
CT and PT assays for at least 6 h after ancrod administra-
tion. In all further experiments, heparin and ancrod were
given 15 or 30 min prior to FAA or TNF to ensure max-
imum inhibition of coagulation.
Warfarin given via the drinking water at above and below
the doses cited by Nawroth et al. (1988) had no effect on
clotting. Hirudin at doses reported to be effective in the clinic
did not increase either CT or PT in our mice. Because of the
expense of this drug, higher doses were not tested. Urokinase
and streptokinase were also ineffective anticoagulants over
Table II Effect of anticoagulants on ex vivo clotting times
Anticoagulants
Time after Heparin Ancrod
treatment CT PT CT PT
(min) (sec) (sec) (sec) (sec)
0 62 20 62 20
(no treatment)
15 dnc dnc dnc -
30 dnc dnc dnc dnc
360 80 18 dnc dnc
The time course for the effect ofheparin and ancrod on the ex vivo
coagulationparametersofmouseplasma. Ancroddosewas 5 Ukg' tail
vein i.v. Time 0 are non-treated mice. dnc = did not clot. Data are the
mean of at least three mice per point.
the dose range tested.
The combination of heparin (500 U kg-') plus FAA (300
mgkg-') was administered to mice and the CT and PT
determined. As expected, the administration of FAA alone
produced a decrease in the clotting time in non-tumour CBA
mice within 30 min post-administration (Murray et al., 1989).
However, when given in combination with heparin, the CT
response was indistinguishable from mice given heparin alone
(data not shown), i.e. no clotting was observed for at least
90 min.
Effects ofagents or circulating platelets numbers
The effect of heparin and ancrod on the number of cir-
culating platelets was measured, either alone or in combina-
tion with FAA. Shown in Figure la are the platelet numbers
for CBA mice bearing CaNT tumour as a function of time
following administration of heparin (2 x 500 U kg-'), FAA
(200 or 300 mgkg-'), or heparin followed 15 min later by
FAA. Heparin alone induced a slight increase in circulating
platelet numbers from 1 h to 4 h, and FAA induced a sharp
decrease in numbers. The combination of FAA and heparin
produced platelet levels identical to FAA alone.
Shown in Figure lb are the platelet numbers following
administration of ancrod (5 U kg-'), FAA (200 or 360
mgkg-'), or ancrod followed 30 min later by FAA. Ancrod
alone induced a slight decrease in the platelet numbers at 6 h
post administration. Again, prior administration of ancrod
did not abrogate the FAA-induced reduction in platelets. In
non-tumour bearing mice, heparin and ancrod had no effect
on the number of circulating platelets either alone or in
combination with FAA (data not shown).
Regrowth delay
Anticoagulants were administered to mice bearing CaNT
tumours of 7-8 mm mean diameter prior to treatment with
FAA (200 mgkg-') or TNF (10 pg/mouse), to determine
whether the antitumour effect of either agent could be
diminished. Heparin was administered 15 min and ancrod
30 min prior to treatment. While both FAA and TNF in-
duced significant growth delay in this tumour (approximately
8 days in each case), heparin did not significantly reduce the
growth delay in either case (Figures 2a and b), nor did
heparin alone affect growth of the tumour. Similar observa-
tions were made with ancrod (Figure 2c and d), which had
no effect on FAA- or TNF-induced growth delay: ancrod
alone had no effect on tumour growth.
Discussion
Studies on an extensive range of anticoagulants (see Table I)
revealed that heparin and ancrod were most effective at
inhibiting ex vivo coagulation of mouse plasma. While FAA
normally reduces clotting time of mouse plasma, when used
in combination with heparin or ancrod, the ex vivo clotting
parameters were dominated by the effect of the anticoagulant
and in most cases plasma from these mice would not clot forEFFECT OF ANTICOAGULANT TREATMENT ON ACTION OF FAA 691
at least several hours aIter FAA aaministration. By this time
levels of circulating FAA following a single dose of 200
mg kg-' have decreased to well below therapeutic levels
(Double et al., 1986; Damia et al., 1988). In terms of growth
delay, however, heparin and ancrod had no effect on the
antitumour action of FAA in the CaNT model. In parallel
experiments neither anticoagulant abrogated the effects of
TNF. This is consistent with a previous report documenting
the inability of heparin to counteract the effects of TNF on
growth of the Meth A tumour (Watanabe et al., 1988),
although it has also been reported that the anticoagulant
dicoumarol does partially block the effects of TNFa (Shi-
momura et al., 1988). Our data suggest that fibrin formation
via the normal coagulation cascade is not a necessary com-
b ponent of the tumour response. Yet a significant body of
)o evidence indicates that a reduction in tumour blood flow may
be a key component of tumour cell killing (Zwi et al., 1989;
Hill et al., 1989; Bibby et al., 1989), and therefore we must
o0l surmise that the reduction in tumour blood flow is mediated
5 U/kg AUC by mechanisms other than vascular occlusion by thrombus
)o + formation. Rapid changes in vascular permeability after FAA
ANC+200 mg/kg FAA treatment (Thurston et al., in prep.) might suffice to cause
)o - r ~~~~~~~~~5 vascular collapse. Alternatively, coagulation mechanisms
- +200 mg/kg FAA might operate within the tumour which do not respond
D0 ANC+300mg/kgFAA +300mg/kgFAA normally to anticoagulants; evidence from in vitro studies 0 AC30mgk0mg/kgFsuggests that tumours elaborate factors which enhance pro-
coagulant activity associated with endothelial cells (Clauss et
o0 o 100 200 300 400 al., 1990; Murray et al., 1991b).
Inhibition of coagulation by heparin or ancrod did not
Time after FAA(mmn) affect the FAA-induced depletion of platelets seen in tumour-
1 The effect ofanticoagulant agents on the FAA-induced bearing mice, implying that platelet depletion is not due to
nption of platelets in CBA mice bearing CaNT tumour. a, platelet adherence to fibrin. Although this phenomenon is
rect of heparin. Heparin was administered twice with a only observed in tumour-bearing mice, mice in which the
interval, each time at a dose of 500 Ukg-'. FAA was blood supply to the tumour is occluded prior to FAA treat-
15 min after the first injection. A, heparin alone; O, ment also show a decrease in the circulating platelet count
gkg-I FAA, *, 200mgkg-' FAA + heparin; 0 300
' FAA; 300mg kg-' FAA + heparin. b, the effect of an- ndicating that platelet consumption after FAA treatment is
Ancrod was given 30min prior to FAA administration. not due to selective accumulation within the tumour (Smith
crod alone; 0, 200mg kg-' FAA; *, 200mgkg-' FAA et al., 1991). Therefore while it appears that fibrin formation
rod, 0, 300mg kg-' FAA; *, 300mg kg-' FAA + anc- via the normal coagulation cascade may not be a necessary
r+ Heparin ,
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Figure 2 The effect of anticoagulant agents on the FAA-induced growth delay of the CaNT tumour. a and b, Tumour bearing
mice were treated with heparin as described, followed by a, FAA (200 mg kg-') or b, TNF (10ltg/mouse). c and d, Tumour bearing
mice were treated with ancrod as described, followed by c, FAA (200mg kg-') or d, TNF (10 g/mouse).
0)
x
0
0) .iD
4c
2C
Figure
consun
the efl
90min
given
200mj
mg kg
crod.
A, ani
+ anc
rod.
14
E
6
6
Time (days)
11
9
71
5
E
6
CD
3
Time (days)
- 1-- IL_____ T'7A A ID_ A-IL.'_
100,
80,
60692 G. THURSTON et al.
component of the tumour response, the cause and possible
role of FAA-induced platelet consumption is yet to be
elucidated.
This work was entirely supported by the Cancer Research Campaign.
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manuscript.
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